We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




PCR Test Can Diagnose Kidney Cancer in Urine

By HospiMedica staff writers
Posted on 18 May 2004
A methylation-specific polymerase chain reaction (CPR) test has shown the ability to identify kidney cancer, including stage 1 cancer, in the urine of patients. More...
Following removal of the cancerous kidney, the test showed no DNA evidence of disease. The findings were presented at the annual meeting of the American Urological Association in San Francisco (CA, USA) in May 2004.

The prognosis for advanced kidney cancer is poor, whereas the early diagnosis of kidney cancer can result in curative treatment. The challenge has been to develop an inexpensive, noninvasive, accurate, and simple screening test. The new urine test meets these criteria. Moreover, when the test was used on urine from control subjects, people without cancer, it showed none of the gene alterations found in the urine of people with cancer.

"We used a common laboratory procedure to test the urine of 50 patients with kidney cancer,” explained Paul Cairns, Ph.D., a molecular biologist at Fox Chase Cancer Center (Philadelphia, PA, USA; www.fccc.edu). "Forty-four of the 50 tests showed gene changes in the urine that were identical to the gene changes found in the tumor tissue taken at the time of surgery.”

The new test searches for six cancer specific tumor-suppressor genes that were altered, causing them to fail in their role of preventing errant cell growth. These six genes are usually identified only after a pathologist's review of tumor tissue. Currently, kidney cancer is diagnosed after radiographic imaging by ultrasound, a computed tomography (CT) scan and/or a magnetic resonance imaging (MRI) scan. A biopsy of a kidney mass can be difficult to interpret or may give a false negative result. There is no protein marker test for kidney cancer as there is for prostate cancer.

"The test appears to be remarkably accurate, with no false-positives in this study,” said lead author Robert G. Uzzo, M.D., a urologic surgeon at Fox Chase Cancer Center. "In addition, one of the most impressive outcomes of this research is that the test also identified 27 of the 30 patients with stage 1 disease.”




Related Links:
Fox Chase Cancer Center

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Tourniquet System
heidi– mein Tourniquet
Patient Monitoring System
AlarmSense
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The new, inexpensive stick-on sweat sensor measures lipid levels, offering a noninvasive way to continuously monitor cholesterol and triglycerides. (Image Credit: California Institute of Technology)

Wearable Patch Enables Continuous Noninvasive Cholesterol and Triglyceride Monitoring

Cholesterol and triglyceride testing typically relies on phlebotomy and intermittent lipid panels, limiting real-time assessment of cardiovascular and metabolic risk. Noninvasive monitoring could reduce... Read more

Surgical Techniques

view channel
Image: Phasix Mesh is a fully resorbable monofilament scaffold designed for rapid tissue incorporation, combining synthetic mesh repair strength with biologic graft-like remodeling. (Photo courtesy of BD)

Resorbable Mesh Evaluated to Prevent Incisional Hernias After Abdominal Surgery

Incisional hernia is a common complication after abdominal surgery and can necessitate additional interventions and prolonged recovery. Preventive strategies remain limited, and there are currently no... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.